Rustam Al-Shahi Salman, Principal Investigator of the the REstart or STop Antithrombotics Randomised Trial (RESTART) (ISRCTN71907627), discusses results and insights from this randomised trial comparing starting versus avoiding antiplatelet drugs for adults surviving antithrombotic-associated intracerebral haemorrhage at 122 hospital sites in the United Kingdom.
Content produced in Milan, Italy and shared with kind authorisation of the European Stroke Organisation (ESO) and the European Stroke Organisation Conference (ESOC 2019).
